Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis

Bibliographic Details
Main Authors:	Coates, LC, Gottlieb, AB, Shuler, CL, Lin, C-Y, Samanta, S, Moriarty, SR, Lee, CH, Mease, PJ
Format:	Conference item
Published:	BMJ 2016

Similar Items

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
by: Coates, L, et al.
Published: (2017)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, LC, et al.
Published: (2022)

Non tropical pharmacological treatment of early, untreated (Dmard-Naïve) psoriatic disease: A systematic review
by: De Marco, G, et al.
Published: (2019)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, L, et al.
Published: (2022)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
by: Ritchlin, CT, et al.
Published: (2023)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
by: Tillett, W, et al.
Published: (2020)

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
by: Tucker, L, et al.
Published: (2022)

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
by: Douglas, K, et al.
Published: (2003)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
by: Edwards, C, et al.
Published: (2008)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
by: Coates, LC, et al.
Published: (2022)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
by: Jobanputra, P, et al.
Published: (2004)

Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
by: Williams, R, et al.
Published: (1999)

To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?
by: van Duren, BH, et al.
Published: (2021)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
by: Coates, LC, et al.
Published: (2021)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
by: Edwards, C, et al.
Published: (2005)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial
by: Watson, M, et al.
Published: (2024)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
by: McInnes, IB, et al.
Published: (2023)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
by: Humby, F, et al.
Published: (2019)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
by: Gladman, DD, et al.
Published: (2018)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
by: Coates, L, et al.
Published: (2018)

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
by: Siebert, S, et al.
Published: (2024)

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis
by: Siebert, S, et al.
Published: (2024)

Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers
by: Cordtz, R, et al.
Published: (2017)

Incidence of knee and hip replacements in rheumatoid arthritis patients following introduction of biological dmards: an interrupted time series analysis using nationwide health care registers
by: Cordtz, R, et al.
Published: (2017)

Psoriatic arthritis: prospects for the future
by: Hackett, S, et al.
Published: (2022)

Outcome measures in psoriatic arthritis: where next?
by: Hackett, S, et al.
Published: (2022)

How should we define disease and outcomes in axial psoriatic arthritis?
by: Coates, LC
Published: (2021)

Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
by: Caporali, R, et al.
Published: (2022)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
by: Kavanaugh, A, et al.
Published: (2024)

Comparative effectiveness of tumour necrosis factor inhibitor therapy vs. conventional synthetic dmards on need for joint replacement among rheumatoid arthritis patients: A propensity score matched analysis of UK registry data
by: Hawley, S, et al.
Published: (2018)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
by: Coates, LC, et al.
Published: (2018)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
by: Soriano, ER, et al.
Published: (2023)

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Taylor, P, et al.
Published: (2013)

Identification of psoriatic arthritis in patients with psoriasis
by: Coates, LC, et al.
Published: (2023)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
by: Fleischmann, R, et al.
Published: (2023)